|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:CEO
|
gptkb:Kevin_Lee
|
|
gptkbp:clinicalTrialPhase
|
gptkb:BT1718
gptkb:BT5528
gptkb:BT8009
|
|
gptkbp:collaboratedWith
|
gptkb:AstraZeneca
gptkb:Cancer_Research_UK
gptkb:Genentech
|
|
gptkbp:countryOfOrigin
|
gptkb:United_Kingdom
|
|
gptkbp:developedBy
|
gptkb:Bicycle_Toxin_Conjugates_(BTCs)
gptkb:Bicycle_tumor-targeted_immune_cell_agonists_(Bicycle_TICAs)
|
|
gptkbp:focusesOn
|
oncology
immuno-oncology
therapeutics based on bicyclic peptides
|
|
gptkbp:foundedIn
|
2009
|
|
gptkbp:founder
|
gptkb:Sir_Gregory_Winter
|
|
gptkbp:headquartersLocation
|
gptkb:Boston,_Massachusetts,_United_States
gptkb:Cambridge,_United_Kingdom
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:listedOn
|
gptkb:London_Stock_Exchange
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:BCYC
|
|
gptkbp:website
|
https://www.bicycletherapeutics.com/
|
|
gptkbp:bfsParent
|
gptkb:Sir_Greg_Winter
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bicycle Therapeutics
|